Expertise in
8
conditions

Dr. Mark R. Gilbert

Otolaryngology
The Board Of Trustees Of The University Of Illinois
1009 S Wood St, Uic Otolaryngology, 
Chicago, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
17 Years of Experience
Expertise in
8
conditions
The Board Of Trustees Of The University Of Illinois
1009 S Wood St, Uic Otolaryngology, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Gilbert is an Otolaryngologist in Chicago, Illinois. Dr. Gilbert has been practicing medicine for over 17 years is highly rated in 8 conditions, according to our data. His top areas of expertise are Spasmodic Dysphonia, Laryngeal Nerve Damage, Vocal Cord Dysfunction, Swallowing Difficulty, and Laryngectomy. Dr. Gilbert is currently accepting new patients.

His clinical research consists of co-authoring 401 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
2009
Specialties
Otolaryngology
Licenses
Otolaryngology in MO
Hospital Affiliations
University Of Illinois Hospital And Clinics
University Of Missouri Health Care
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
1009 S Wood St, Uic Otolaryngology, Chicago, IL 60612

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Enrollment Status: Recruiting
Publish Date: December 18, 2025
Intervention Type: Drug
Study Drug: ONC206
Study Phase: Phase 1
Evaluation of the Natural History of and Specimen Banking for Patients With Tumors of the Central Nervous System
Evaluation of the Natural History of and Specimen Banking for Patients With Tumors of the Central Nervous System
Enrollment Status: Completed
Publish Date: January 16, 2026
Intervention Type: Other
Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: December 23, 2025
Intervention Type: Drug
Study Drugs: TMZ, Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase II Trial of Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A)Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
A Phase II Trial of Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A)Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
Enrollment Status: Completed
Publish Date: August 11, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double Blind Phase II Trial of Surgery, Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
A Randomized, Double Blind Phase II Trial of Surgery, Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
Enrollment Status: Terminated
Publish Date: August 08, 2025
Intervention Type: Other, Drug, Biological, Procedure
Study Drugs: Pembrolizumab, Temozolomide, Heat Shock Protein Peptide Complex-96 Vaccine
Study Phase: Phase 2
Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center Trial
Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center Trial
Enrollment Status: Completed
Publish Date: August 05, 2025
Intervention Type: Drug
Study Drugs: Carboplatin, Bevacizumab
Study Phase: Phase 2
Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers
Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers
Enrollment Status: Completed
Publish Date: June 29, 2025
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
Phase II Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
Phase II Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: November 22, 2023
Intervention Type: Drug
Study Drug: LB-100
Study Phase: Phase 2
Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients With Newly Diagnosed Glioblastoma
Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Biological, Other, Drug
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 1
View 8 Less Clinical Trials

401 Total Publications

Managing Cancer and Living Meaningfully Therapy Delivered as a novel remote intervention in individuals diagnosed with a Primary Central Nervous System Tumor.
Managing Cancer and Living Meaningfully Therapy Delivered as a novel remote intervention in individuals diagnosed with a Primary Central Nervous System Tumor.
Journal: medRxiv : the preprint server for health sciences
Published: January 16, 2026
Similar Doctors
Expertise in
28
conditions
Dr. John P. Leonetti
Otolaryngology
Expertise in
28
conditions
Dr. John P. Leonetti
Otolaryngology

Loyola University Medical Center

2160 S 1st Ave, 
Maywood, IL 
 (8.5 miles away)
708-216-9000
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Leonetti is an Otolaryngologist in Maywood, Illinois. Dr. Leonetti has been practicing medicine for over 44 years is highly rated in 28 conditions, according to our data. His top areas of expertise are Schwannoma, Facial Paralysis, Acoustic Neuroma, Mastoidectomy, and Nerve Decompression. Dr. Leonetti is currently accepting new patients.

Robert C. Kern
Expertise in
8
conditions
Dr. Robert C. Kern
Otolaryngology
Expertise in
8
conditions
Dr. Robert C. Kern
Otolaryngology
675 N St Clair St Ste 15-200, Galter Pavilion, 
Chicago, IL 
 (3.5 miles away)
312-695-8182
Experience:
41+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robert Kern is an Otolaryngologist in Chicago, Illinois. Dr. Kern has been practicing medicine for over 41 years is highly rated in 8 conditions, according to our data. His top areas of expertise are Nasal Polyps, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Asthma, Endoscopy, and Nerve Decompression.

Bruce K. Tan
Expertise in
7
conditions
Dr. Bruce K. Tan
Otolaryngology
Expertise in
7
conditions
Dr. Bruce K. Tan
Otolaryngology
675 N St Clair St Ste 15-200, Galter Pavilion, 
Chicago, IL 
 (3.5 miles away)
312-695-8182
Experience:
22+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Bruce Tan is an Otolaryngologist in Chicago, Illinois. Dr. Tan has been practicing medicine for over 22 years is highly rated in 7 conditions, according to our data. His top areas of expertise are Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Nasal Polyps, Sinusitis, Endoscopy, and Nerve Decompression.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gilbert's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile